Related Experiment Video
Updated: Feb 14, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
An Approach to Children with Pulmonary Edema at High Altitude
Deborah R Liptzin1, Steven H Abman1, Ann Giesenhagen2
11 Breathing Institute and Pediatric Heart-Lung Center, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado , Aurora, Colorado.
Insights
High-altitude pulmonary edema (HAPE) in children is challenging to diagnose and can be fatal. Evaluation for underlying heart conditions is crucial for treatment and prevention strategies.
Area of Science:
- Pediatric Medicine
- Altitude Medicine
- Pulmonary Medicine
Background:
- Diagnosing high-altitude illness in children, particularly preverbal ones, presents unique challenges.
- Families traveling to high altitudes for recreation may seek guidance or present after illness onset.
- High-altitude pulmonary edema (HAPE) is a potentially fatal condition in children.
Purpose of the Study:
- To outline an approach for diagnosing and managing high-altitude pulmonary edema (HAPE) in children.
- To discuss the susceptibility of children to HAPE and associated risk factors.
- To emphasize the importance of evaluating for underlying cardiopulmonary conditions in pediatric HAPE cases.
Main Methods:
- Review of existing literature and clinical observations regarding pediatric HAPE.
- Discussion of different HAPE scenarios in children: classic, reentry, and high-altitude resident pulmonary edema (HARPE).
- Highlighting physiological factors contributing to HAPE susceptibility in children.
Main Results:
- Children may develop HAPE during travel to high altitudes, upon return to high-altitude homes, or with respiratory illness at high altitudes.
- Children exhibit increased susceptibility due to vascular reactivity, immature breathing control, and frequent respiratory illnesses.
- Evaluation for structural heart disease and pulmonary hypertension is recommended for children with HAPE.
Conclusions:
- Children with HAPE require thorough investigation for underlying cardiopulmonary abnormalities.
- Treatment involves supplemental oxygen and descent, with consideration of pre-existing conditions.
- Further research is needed to optimize HAPE prevention and treatment strategies in pediatric populations.
Abstract:
Liptzin, Deborah R., Steven H. Abman, Ann Giesenhagen, and D. Dunbar Ivy. An approach to children with pulmonary edema at high altitude. High Alt Med Biol. 19:91-98, 2018.
Introduction:
Diagnosis of high-altitude illness can be more challenging in children, especially those who are preverbal. Families often travel to high elevations for family vacations, either for skiing, hiking, and/or camping. They may present to their primary care providers looking for anticipatory guidance before travel or may follow-up after developing high-altitude illness. High-altitude pulmonary edema (HAPE) can be fatal.
Observations:
There is no indication for HAPE prophylaxis in altitude naive children. Children may develop HAPE either when traveling from low altitude to high altitude for vacation (classic HAPE), when returning to high-altitude homes after travel to low altitude (reentry HAPE), or even with a respiratory illness at high altitude without any change in elevation (high-altitude resident pulmonary edema or HARPE). Children may be more susceptible to HAPE because of increased vascular reactivity, immature control of breathing, and increased frequency of respiratory illnesses. Children with HAPE warrant evaluation for underlying cardiopulmonary abnormalities, including structural heart disease and pulmonary hypertension. Treatment of HAPE includes supplemental oxygen and descent, but underlying cardiopulmonary disease may also help guide treatment and prevention.
Conclusions And Relevance:
Evaluation for structural heart disease and pulmonary hypertension should be considered in children with HAPE. Future studies should be done to elucidate the optimal strategies for prevention and treatment of HAPE and to better understand the development of HAPE in children.
Related Concept Videos
Drug Dosing: Infants and Children
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Other Pulmonary Disorders
Frustration and Conflict: Approach-Approach, Approach-Avoidance
One common type of conflict is the Approach–Approach Conflict. In this case, a person faces two desirable...

